What is the effect of dihydropyridine CCBs on graft loss in kidney transplant recipients?
The evidence review, including both hypertensive and normotensive patients, has found that, compared to placebo, CCB use caused a mean 26% reduction in graft loss (RR: 0.74; 95% CI). When these medication classes were examined separately, only the dihydropyridine CCB group caused a 38% reduction in graft loss (RR: 0.62; 95% CI: 0.43 0.90) over a mean of 25 months compared to placebo.